司库奇尤单抗治疗胫前银屑病的快速疗效：RESOLVE研究。
Rapid Efficacy of riSankizumab in pretibial psoriasis invOLVEment: RESOLVE.
作者信息
Bernardini Nicoletta, Skroza Nevena, Atzori Laura, Mugheddu Cristina, Megna Matteo, Cacciapuoti Sara, Ortoncelli Michela, Montesu Maria A, Carpentieri Antonio, Carriero Martino, Atzori Maria G, Addis Gianmario, Balestri Riccardo, Rech Giulia, Bruni Pierluigi, Papini Manuela, Potenza Concetta
机构信息
Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
Department Medical Sciences and Public Health, University of Cagliari, Italy.
出版信息
Drugs Context. 2024 Sep 5;13. doi: 10.7573/dic.2024-6-3. eCollection 2024.
BACKGROUND
Despite extraordinary improvements in the management of psoriasis in recent times, some areas of the body, such as the pretibial area, still show an unsatisfactory response and a more significant impact on patient quality of life. This multicentre study focuses on psoriasis affecting sensitive areas (particularly the pretibial area), its impact on quality of life and the therapeutic response to risankizumab.
METHODS
This multicentre prospective observational study recruited patients with moderate-to-severe psoriasis with pretibial area involvement. All patients underwent treatment with risankizumab (150 mg every 3 weeks), and efficacy was assessed after 24 weeks.
RESULTS
The study included 128 patients with a mean age of 51 years, suffering from moderate-to-severe psoriasis with involvement of the pretibial area with median total Psoriasis Area Severity Index score of 17.05 and Dermatology Life Quality Index of 16.27. The group was further divided into two sub-groups: the 'mother patch' group, in whom the very first psoriatic plaque appeared in the pretibial region (45 patients), and the 'non-mother patch' group, in whom the psoriatic lesion in the pretibial region was present but not as the first manifestation (83 patients). In order to better assess the involvement of psoriasis in the pretibial area, the pretibial plaque lesion severity index was also calculated at baseline in all patients: extent 2.75, erythema 2.64, infiltration 2.45 and desquamation 2.38. All participants in this study showed a good therapeutic response, with a reduction in all scores.
CONCLUSIONS
The pretibial area is becoming an object of therapeutic interest due to some resistance to clearance and the consequent impairment of patient quality of life. This study showed that risankizumab can give favourable therapeutic results not only in patients with moderate-to-severe psoriasis with involvement of the difficult-to-treat areas but particularly in patients with recalcitrant plaques in the pretibial area.
背景
尽管近年来银屑病的管理有了显著改善，但身体的某些部位，如胫前区，仍显示出不尽人意的反应，对患者生活质量的影响更为显著。这项多中心研究聚焦于影响敏感区域（特别是胫前区）的银屑病、其对生活质量的影响以及对司库奇尤单抗的治疗反应。
方法
这项多中心前瞻性观察性研究招募了胫前区受累的中度至重度银屑病患者。所有患者均接受司库奇尤单抗治疗（每3周150mg），并在24周后评估疗效。
结果
该研究纳入了128例平均年龄为51岁的患者，患有中度至重度银屑病，胫前区受累，银屑病面积和严重程度指数总分中位数为17.05，皮肤病生活质量指数为16.27。该组进一步分为两个亚组：“母斑”组，即第一个银屑病斑块出现在胫前区的患者（45例），以及“非母斑”组，即胫前区存在银屑病病变但不是首发表现的患者（83例）。为了更好地评估银屑病在胫前区的受累情况，所有患者在基线时还计算了胫前斑块病变严重程度指数：范围2.75、红斑2.64、浸润2.45和脱屑2.38。本研究的所有参与者均显示出良好的治疗反应，所有评分均降低。
结论
由于清除存在一定阻力以及随之而来的患者生活质量受损，胫前区正成为治疗关注的对象。这项研究表明，司库奇尤单抗不仅可以在中度至重度银屑病且累及难治性区域的患者中取得良好治疗效果，特别是在胫前区有顽固性斑块的患者中。
Zotero 插件